Publication: A Comparative Effectiveness Analysis Applying a 3-Way Propensity Score Matching to Real-World Data from the MSBase Registry in Preparation for a Cost-Effectiveness Model: Patients Switching Within First-Line Agents or to Either Natalizumab or Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
…
Description
70th Annual Meeting of the American-Academy-of-Neurology (AAN) -- APR 21-27, 2018 -- Los Angeles, CA
Keywords
Citation
WoS Q
Scopus Q
Source
Volume
90
